Tarek Yousry
About
In The Last Decade
Tarek Yousry
319 papers receiving 16.0k citations
Hit Papers
Peers
Comparison fields: 5 of 181
- Neurology 5.7k
- Pathology and Forensic Medicine 5.1k
- Radiology, Nuclear Medicine and Imaging 4.1k
- Cognitive Neuroscience 3.2k
- Neurology 2.6k
Countries citing papers authored by Tarek Yousry
This map shows the geographic impact of Tarek Yousry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tarek Yousry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tarek Yousry more than expected).
Fields of papers citing papers by Tarek Yousry
This network shows the impact of papers produced by Tarek Yousry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tarek Yousry. The network helps show where Tarek Yousry may publish in the future.
Co-authorship network of co-authors of Tarek Yousry
This figure shows the co-authorship network connecting the top 25 collaborators of Tarek Yousry. A scholar is included among the top collaborators of Tarek Yousry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tarek Yousry. Tarek Yousry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 11 | |
| 2 | 5 | |
| 3 | 26 | |
| 4 | 14 | |
| 5 | 14 | |
| 6 | 49 | |
| 7 | Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results | 1 |
| 8 | 71 | |
| 9 | MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process (vol 11, pg 471, 2015) | 0 |
| 10 | 120 | |
| 11 | Effects of BG-12 on magnetic resonance imaging outcomes in CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis), a randomized, placebo-controlled, phase 3 study | 3 |
| 12 | Clinical and neuroimaging outcomes with BG-12 treatment in CONFIRM (comparator and an oral fumarate in relapsing-remitting multiple sclerosis), a multicenter, randomized, placebo-controlled, phase-3 study | 2 |
| 13 | 237 | |
| 14 | 179 | |
| 15 | The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions | 2 |
| 16 | Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study | 13 |
| 17 | Advanced magnetic resonance imaging techniques demonstrate occult abnormalities in focal epilepsy | 1 |
| 18 | 5 | |
| 19 | 30 | |
| 20 | 27 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.